Author

T. Powles

h-index 110 View on Semantic Scholar

We have 2 of 1,181 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

85 Phase 3 LITESPARK-033 (NCT07227402) Study of Belzutifan Plus Zanzalintinib Versus Cabozantinib for Recurrent Clear Cell Renal Cell Carcinoma During or After Adjuvant Anti–PD-(L)1 Therapy

Abstract Background Adjuvant pembrolizumab is the standard of care for patients with renal cell carcinoma (RCC) at increased risk for recurrence after nephrectomy. However, treatment options are needed following adjuvant anti–PD-(L)1 therapy because none of the currently available treatments for advanced RCC were evalu...

T. Choueiri, T. Powles, M. Voss et al. · The Oncologist · 0 citations

Open access Sep 2026

20 PF-08634404 (SSGJ-707), a Tetravalent PD-1/VEGF Bispecific Antibody for the Treatment of Renal Cell Carcinoma (NCT07227415)

Abstract Background Renal cell carcinoma (RCC) is characterized by an immunogenic tumor microenvironment and frequent activation of angiogenic pathways. Therefore, combining immune checkpoint blockade with VEGF pathway inhibition is a rational therapeutic approach. PF‑08634404 is an investigational anti–PD‑1 and anti‑V...

T. Choueiri, S. Pal, T. Powles et al. · The Oncologist · 0 citations